August 3, 2017 09:41 AM EDTUpdated 12:14 PM
Pharma

FDA of­fers an­oth­er speedy can­cer drug OK, ap­prov­ing Jazz’s Vyx­eos for acute myeloid leukemia

Shehla Shakoor

Managing Director

In just the lat­est case of a can­cer drug sped along by the FDA, Jazz Phar­ma­ceu­ti­cals $JAZZ to­day won ap­proval for Vyx­eos (CPX-351) as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

HHS can re­quire ap­proval for drug­mak­ers to ap­ply 340B re­bate mod­els, court rules

A service from the Financial Times